Nuformix Plc (1RT) Stock Price & Analysis
1RT Stock Chart & Stats
- Day’s Range
- EUR 0.02 - EUR 0.02
- 52-Week Range
- EUR 0.02 - EUR 0.02
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 3,000
- Market Cap
- EUR 3.35M
- Enterprise Value
- EUR 2.97T
- Total Cash (Recent Filing)
- EUR 930.28K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -0.57
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
The absence of debt limits interest obligations and refinancing exposure, giving Nuformix greater flexibility than a similarly loss-making company with leverage. This provides some capacity to direct future funding toward development activities, although the small asset base remains a constraint.
Focused Inhaled Drug Pipeline
A focused inhaled-therapy strategy gives Nuformix a defined scientific direction in respiratory and fibrotic lung diseases. Improving local delivery and reducing systemic exposure could create product differentiation if clinical development validates the formulations and attracts commercial partners.
Lower 2025 Net Loss
The substantial reduction in annual net loss suggests that the company may have tightened costs or benefited from fewer exceptional pressures. If maintained, a smaller loss base could extend available resources and reduce the funding required to advance its development pipeline.
Bears Say
No Recent Revenue
Persistent zero revenue indicates that Nuformix has not yet established a meaningful commercial or partnering income stream. This leaves near-term progress dependent on advancing drug candidates toward licensing, milestones, or royalties rather than funding operations through recurring sales.
Persistent Cash Burn
Ongoing negative operating and free cash flow means the company consumes cash while its pipeline remains under development. Continued burn increases dependence on external funding and could restrict the pace of research, clinical work, or partnership activity if financing is not secured.
Shrinking Financial Base
Although Nuformix has no debt, the material contraction in equity and assets reduces its financial buffer against continuing losses and development costs. A smaller capital base can limit strategic flexibility and make future funding more important to sustaining the business.
1RT FAQ
What was Nuformix Plc’s price range in the past 12 months?
What is Nuformix Plc’s market cap?
When is Nuformix Plc’s upcoming earnings report date?
How were Nuformix Plc’s earnings last quarter?
Is Nuformix Plc overvalued?
Does Nuformix Plc pay dividends?
What is Nuformix Plc’s EPS estimate?
How many shares outstanding does Nuformix Plc have?
What happened to Nuformix Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nuformix Plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel John Gooding
- Employees
- 3
- Website
- www.nuformix.com
- Address
- 60 Gracechurch Street, London, GL, EC3V 0HR, GB
